For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

17th Dec 19

Investor Conference Call - 18 December 2019

Prior to the opening of the market on 18 December 2019, Pharmaxis Ltd (PXS) will announce the advice the company has received from Boehringer Ingelheim (BI) concerning BI’s future development plans for the drug it acquired from Pharmaxis in 2015.

That announcement will have the effect of lifting the current trading halt over the company’s shares.

The company will hold an investor teleconference at 9.15am (AEDT) after release of the announcement.

Conference call access information is detailed in the attached.

Read full media release - pdf
30th Oct 19

Pharmaxis Science Update Outlines Scope for Anti-Fibrotic Pipeline

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today provided an update on the company’s anti-fibrotic drug pipeline highlighting both the therapeutic areas of interest and competitive positioning of its LOXL2 and pan LOX inhibitors.

Speaking at the 2019 AusBiotech conference in Melbourne, Australia, Pharmaxis CEO Gary Phillips outlined the steps Pharmaxis has taken to develop a best in class status for its Lysyl oxidase like 2 (LOXL2) inhibitors and strong pre-clinical data in myelofibrosis for its pan-LOX inhibitor PXS-5505.

Read full media release - pdf
28th Oct 19

FDA Provides Guidance on Bronchitol Approval Steps - FDA Expected to Complete Review Q2 2020

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced its US licensee Chiesi Group (Chiesi) has received detailed advice from the US Food and Drug Administration (FDA) on its plan to fulfil the requirements necessary to approve Bronchitol® (mannitol) for the treatment of adult cystic fibrosis patients in the United States. Based on this feedback Chiesi has added an additional month to its timetable. The FDA review of the Bronchitol NDA is therefore now expected to be completed in the second quarter of 2020.

Read full media release - pdf